Brief: Galera Announces Primary Endpoint Met Statistical Significance In Corrected Topline Data Of Avasopasem Phase 3 Trial

Galera Therapeutics

14/12/2021 12:16

Dec 14 (Reuters) - Galera Therapeutics Inc  GRTX.O :
    * GALERA ANNOUNCES PRIMARY ENDPOINT MET STATISTICAL
SIGNIFICANCE
IN CORRECTED TOPLINE EFFICACY DATA OF PHASE 3 ROMAN TRIAL OF
AVASOPASEM
    * GALERA - CORRECTED TOPLINE PHASE 3 ROMAN DATA SHOW PRIMARY
ENDPOINT ACHIEVED STATISTICAL SIGNIFICANCE IN REDUCING INCIDENCE
OF RADIOTHERAPY-INDUCED SEVERE ORAL MUCOSITIS
    * GALERA THERAPEUTICS INC - TOPLINE RESULTS FROM SINGLE-ARM
PHASE
2A TRIAL OF AVASOPASEM IN EUROPE IN LINE WITH ROMAN TRIAL
RESULTS
    * GALERA THERAPEUTICS INC - COMPANY PLANS TO DISCUSS
AVASOPASEM
DATA WITH FDA IN 2022

Source text for Eikon:  ID:nGNXp35Yp 
Further company coverage:  GRTX.O 

 ((Reuters.Briefs@thomsonreuters.com;))